SCHEMBL4135020

SCHEMBL4135020

CC(C)(C)c1cc2c(cc1I)OCO2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PGR P06401 1/20 0.33
AR P10275 1/20 0.33
GABRA1 P14867 1/20 0.33
MAOA P21397 1/20 0.33
SLC6A2 P23975 1/20 0.33
PDE4A P27815 1/20 0.33
KDR P35968 1/20 0.33
GABRB2 P47870 1/20 0.33
SLC6A3 Q01959 1/20 0.33
ATM Q13315 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.31
MAPK9 P45984 2/20 0.31
HPGD P15428 1/20 0.31
CHRNA7 P36544 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6364660 0.84 CYP3A4 (0.39) CYP3A4LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL18308983 0.77 ALOX5 (0.38) CYP3A4ALDH1A1SMN1; SMN2PGRAR
SCHEMBL1742802 0.77 CYP3A4 (0.44) CYP3A4ALDH1A1MAPK1SMN1; SMN2ATM
SCHEMBL31709528 0.77 CYP3A4 (0.44) CYP3A4ALDH1A1MAPK1SMN1; SMN2ATM
SCHEMBL4995839 0.75 MAPT (0.43) CYP3A4ALDH1A1MAPK1SMN1; SMN2PGR
SCHEMBL21363801 0.75 ALOX15 (0.56) CYP3A4LMNAALDH1A1MAPK1SMN1; SMN2
SCHEMBL7440407 0.75 CYP3A4 (0.33) CYP3A4LMNAALDH1A1PGRAR
SCHEMBL12203329 0.75 PTGS2 (0.37) CYP3A4LMNAALDH1A1PGRAR
SCHEMBL8248216 0.75 ALDH1A1 (0.40) CYP3A4ALDH1A1SMN1; SMN2PGRAR
SCHEMBL24008355 0.73 ALDH1A1 (0.40) CYP3A4LMNAALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2023-06-22 US disclosed
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors Guris, Inc. (US) 2023-01-24 US disclosed
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2021-09-23 US disclosed
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2020-11-24 US disclosed
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2020-02-27 US disclosed
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2019-10-01 US disclosed
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2019-01-10 US disclosed
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2018-07-31 US disclosed
US-20170267674-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2017-09-21 US disclosed
US-9630965-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2017-04-25 US disclosed
US-20160058742-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2016-03-03 US disclosed
US-9040556-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2015-05-26 US disclosed
US-20140221343-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2014-08-07 US disclosed
US-8586605-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2013-11-19 US disclosed
EP-2069324-B1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS INC (US) 2013-07-31 EP disclosed
US-8324240-B2 Fused amino pyridine as HSP90 inhibitors CURIS, INC. (US) 2012-12-04 US disclosed
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2012-09-20 US disclosed
EP-2069324-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS Curis, Inc. (US) 2009-06-17 EP disclosed
WO-2008115719-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. (US) 2008-09-25 WO disclosed
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS CURIS, INC. 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190010152-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-10428068-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20170267674-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20160058742-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20120237508-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20230192687-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20080234314-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20210292317-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20200062754-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-20140221343-A1 FUSED AMINO PYRIDINE AS HSP90 INHIBITORS HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-11560377-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-10844056-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885
US-10035797-B2 Fused amino pyridine as HSP90 inhibitors HSP90B1, HSP90AB1, HSP90AB2P CYP3A4 4236/4885LMNA 4612/4885ALDH1A1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.